stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Gross margin
ACADIA Pharmaceuticals Inc.'s gross margin over the twelve months to 30 September 2026 was 90.5%, down 1.2 percentage points from fiscal 2025 (91.7%). Over the past ten years it has ranged from 82.3% (fiscal 2016) to 100.0% (fiscal 2015); the current reading is higher than 27% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 91.7% | 0.23 |
| FY2024 | 91.5% | (2.81) |
| FY2023 | 94.3% | (3.76) |
| FY2022 | 98.0% | 1.98 |
| FY2021 | 96.1% | (1.64) |
| FY2020 | 97.7% | 1.04 |
| FY2019 | 96.7% | 2.18 |
| FY2018 | 94.5% | 1.74 |
| FY2017 | 92.7% | 10.47 |
| FY2016 | 82.3% | (17.74) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 89.8% | (1.06) |
| Jun 2026 | 90.8% | 0.06 |
| Mar 2026 | 90.8% | (0.02) |
| Dec 2025 | 90.8% | (1.46) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RLAY Relay Therapeutics, Inc. compare | 100.0% |
| TNGX Tango Therapeutics, Inc. compare | 100.0% |
| ACAD ACADIA Pharmaceuticals Inc. | 90.5% |
| XENE Xenon Pharmaceuticals Inc. compare | 28.4% |
| DYN Dyne Therapeutics, Inc. compare | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| VKTX Viking Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement